ESC Premium Access

Burden of atrial fibrillation and risk of stroke: a systematic review

Congress Presentation

About the speaker

Mr Steven Bernard Uittenbogaart

Amsterdam UMC, University of Amsterdam, Amsterdam (Netherlands (The))
1 presentation
0 follower

24 more presentations in this session

Patients with atrial fibrillation treated with apixaban are less likely to discontinue study drug when compared with warfarin: insights from the ARISTOTLE trial

Speaker: Professor D. Xavier (Bangalore, IN)


Incidence of intracranial hemorrhage in the years 2013-15 in patients with atrial fibrillation in anticoagulant therapy: preliminary analysis of data from Ravenna registers

Speaker: Doctor C. Gatti (Ravenna, IT)


High SAMe-TT2R2 score, labile INR and major adverse outcomes in a real life cohort of anticoagulated patients with non-valvular atrial fibrillation

Speaker: Doctor D. Iglesias (Santiago de Compostela, ES)


CHA2DS2-Vasc score, as well as age and body mass index as the main risk factors of brain lesions in asymptomatic patients with paroxysmal non-valvular atrial fibrillation

Speaker: Doctor J. Wieczorek (Katowice, PL)


Novel oral anticoagulants in a real-world cohort of patients undergoing catheter ablation of atrial fibrillation

Speaker: Doctor A. Parwani (Berlin, DE)


Access the full session

Poster session 3 - Anticoagulation in atrial fibrillation III

Speakers: Mr S. Uittenbogaart, Professor D. Xavier, Doctor C. Gatti, Doctor D. Iglesias, Doctor J. Wieczorek...

About the event


ESC Congress 2016

27 August - 31 August 2016

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb